Oncology News | pharmaphorum

News

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

News

Ignota's co-founder and chief executive, Sam Windsor

Ignota vacuums up Kronos Bio's drug programmes

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

News

Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi

Regulatory T-cell scientist trio wins Nobel Prize

The Nobel Prize in Physiology or Medicine goes to three scientists for their work on regulatory T-cells, spawning hundreds of trials of new therapies.

News

Dr Ken Macnamara, Trogenix's chief executive

UK's Trogenix raises £70m for cancer immunotherapy platform

Edinburgh-based Trogenix has raised £70m to fund clinical trials of its triple-acting immunotherapies for brain and colorectal cancers.

News

Delayed TNBC readout for Datroway delivers survival benefit

AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

Ignota vacuums up Kronos Bio's drug programmes

Regulatory T-cell scientist trio wins Nobel Prize

UK's Trogenix raises £70m for cancer immunotherapy platform

Delayed TNBC readout for Datroway delivers survival benefit

Jazz, Roche combo cleared by FDA for lung cancer

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks